In colon carcinogenesis, the cytoskeletal protein gelsolin is down-regulated during the transition from adenoma to carcinoma

Human Pathology

Volumn 39, Issue 10, 2008, Pages 1420-1430

  Gay, Fabien ^a,b,c   Estornes, Yann ^a,b,c   Saurin, Jean Christophe ^a,b,c   Joly Pharaboz, Marie Odile ^a,b,c,d   Friederich, Evelyne ^e   Scoazec, Jean Yves ^a,b,c,d   Abello, Jacques ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e UNIVERSITY OF LUXEMBOURG   (Luxembourg)

Author keywords

Adenocarcinoma; Adenoma; Colon; Gelsolin; Immunohistochemistry

Indexed keywords

GELSOLIN; MESSENGER RNA;

ARTICLE; CANCER STAGING; COLON ADENOMA; COLON CARCINOMA; COLON INJURY; COLON RESECTION; CONTROLLED STUDY; DOWN REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADENOMA; AGED; CELL COUNT; CELL TRANSFORMATION, NEOPLASTIC; COLECTOMY; COLON; COLONIC NEOPLASMS; DOWN-REGULATION; FEMALE; GELSOLIN; HUMANS; IMMUNOENZYME TECHNIQUES; INTESTINAL MUCOSA; LYMPH NODES; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEOPLASM STAGING; RNA, MESSENGER; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 50949126005     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.02.020     Document Type: Article

References (36)

1. Friedl P., and Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3 (2003) 362-374
2. Yamazaki D., Kurisu S., and Takenawa T. Regulation of cancer cell motility through actin reorganization. Cancer Sci 96 (2005) 379-386
3. dos Remedios C.G., Chhabra D., Kekic M., et al. Actin binding proteins: regulation of cytoskeletal microfilaments. Physiol Rev 83 (2003) 433-473
4. Kwiatkowski D.J. Functions of gelsolin: motility, signaling, apoptosis, cancer. Curr Opin Cell Biol 11 (1999) 103-108
5. Witke W., Sharpe A.H., Hartwig J.H., Azuma T., Stossel T.P., and Kwiatkowski D.J. Hemostatic, inflammatory, and fibroblast responses are blunted in mice lacking gelsolin. Cell 81 (1995) 41-51
6. Azuma T., Witke W., Stossel T.P., Hartwig J.H., and Kwiatkowski D.J. Gelsolin is a downstream effector of rac for fibroblast motility. EMBO J 17 (1998) 1362-1370
7. Lu M., Witke W., Kwiatkowski D.J., and Kosik K.S. Delayed retraction of filopodia in gelsolin null mice. J Cell Biol 138 (1997) 1279-1287
8. Cunningham C.C., Stossel T.P., and Kwiatkowski D.J. Enhanced motility in NIH 3T3 fibroblasts that overexpress gelsolin. Science 251 (1991) 1233-1236
9. De Corte V., Bruyneel E., Boucherie C., Mareel M., Vandekerckhove J., and Gettemans J. Gelsolin-induced epithelial cell invasion is dependent on Ras-Rac signaling. EMBO J 21 (2002) 6781-6790
10. Dong Y., Asch H.L., Medina D., Ip C., Ip M., Guzman R., et al. Concurrent deregulation of gelsolin and cyclin D1 in the majority of human and rodent breast cancers. Int J Cancer 81 (1999) 930-938
11. Winston J.S., Asch H.L., Zhang P.J., Edge S.B., Hyland A., and Asch B.B. Downregulation of gelsolin correlates with the progression to breast carcinoma. Breast Cancer Res Treat 65 (2001) 11-21
12. Dosaka-Akita H., Hommura F., Fujita H., et al. Frequent loss of gelsolin expression in non-small cell lung cancers of heavy smokers. Cancer Res 58 (1998) 322-327
13. Lee H.K., Driscoll D., Asch H., Asch B., and Zhang P.J. Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate. Prostate 40 (1999) 14-19
14. Rao J., Seligson D., Visapaa H., et al. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma. Cancer 95 (2002) 1247-1257
15. Visapaa H., Bui M., Huang Y., et al. Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology 61 (2003) 845-850
16. Kim J.H., Choi Y.K., Kwon H.J., Yang H.K., Choi J.H., and Kim D.Y. Downregulation of gelsolin and retinoic acid receptor beta expression in gastric cancer tissues through histone deacetylase 1. J Gastroenterol Hepatol 19 (2004) 218-224
17. Noske A., Denkert C., Schober H., et al. Loss of gelsolin expression in human ovarian carcinomas. Eur J Cancer 41 (2005) 461-469
18. Tanaka M., Mullauer L., Ogiso Y., et al. Gelsolin: a candidate for suppressor of human bladder cancer. Cancer Res 55 (1995) 3228-3232
19. Fujita H., Okada F., Hamada J., et al. Gelsolin functions as a metastasis suppressor in B16-BL6 mouse melanoma cells and requirement of the carboxyl-terminus for its effect. Int J Cancer 93 (2001) 773-780
20. Sazawa A., Watanabe T., Tanaka M., et al. Adenovirus mediated gelsolin gene therapy for orthotopic human bladder cancer in nude mice. J Urol 168 (2002) 1182-1187
21. Tanaka H., Shirkoohi R., Nakagawa K., et al. siRNA gelsolin knockdown induces epithelial-mesenchymal transition with a cadherin switch in human mammary epithelial cells. Int J Cancer 118 (2006) 1680-1691
22. Mielnicki L.M., Ying A.M., Head K.L., Asch H.L., and Asch B.B. Epigenetic regulation of gelsolin expression in human breast cancer cells. Exp Cell Res 249 (1999) 161-176
23. Primeau M., Gagnon J., and Momparler R.L. Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2′-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int J Cancer 103 (2003) 177-184
24. Porter R.M., Holme T.C., Newman E.L., Hopwood D., Wilkinson J.M., and Cuschieri A. Monoclonal antibodies to cytoskeletal proteins: an immunohistochemical investigation of human colon cancer. J Pathol 170 (1993) 435-440
25. Furuuchi K., Fujita H., Tanaka M., et al. Gelsolin as a suppressor of malignant phenotype in human colon cancer. Tumor Target 2 (1997) 277-283
26. Zhang L., Zhou W., Velculescu V.E., et al. Gene expression profiles in normal and cancer cells. Science 276 (1997) 1268-1272
27. Bertucci F., Salas S., Eysteries S., et al. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 23 (2004) 1377-1391
28. De Craene B., Gilbert B., Stove C., Bruyneel E., van Roy F., and Berx G. The transcription factor snail induces tumor cell invasion through modulation of the epithelial cell differentiation program. Cancer Res 65 (2005) 6237-6244
29. WHO classification of tumours-pathology and genetics of tumours of digestive system (2000), WHO Press, Geneva, Switzerland
30. Schlemper R.J., Riddell R.H., Kato Y., et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 47 (2000) 251-255
31. Boland C.R., Thibodeau S.N., Hamilton S.R., et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58 (1998) 5248-5257
32. Yao T., Kouzuki T., Kajiwara M., Matsui N., Oya M., and Tsuneyoshi M. 'Serrated' adenoma of the colorectum, with reference to its gastric differentiation and its malignant potential. J Pathol 187 (1999) 511-517
33. Thompson C.C., Ashcroft F.J., Patel S., et al. Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut 56 (2007) 95-106
34. Shieh D.B., Godleski J., Herndon J.E., et al. Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression. Cancer 85 (1999) 47-57
35. Rao J. Targeting actin remodeling profiles for the detection and management of urothelial cancers-a perspective for bladder cancer research. Front Biosci 7 (2002) e1-e8
36. Shieh D.B., Chen I.W., Wei T.Y., et al. Tissue expression of gelsolin in oral carcinogenesis progression and its clinicopathological implications. Oral Oncol 42 (2006) 599-606